TY - JOUR
T1 - Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
AU - Peng, Kah Whye
AU - Carey, Timothy
AU - Lech, Patrycja
AU - Vandergaast, Rianna
AU - Muñoz-Alía, Miguel
AU - Packiriswamy, Nandakumar
AU - Gnanadurai, Clement
AU - Krotova, Karina
AU - Tesfay, Mulu
AU - Ziegler, Christopher
AU - Haselton, Michelle
AU - Sevola, Kara
AU - Lathrum, Chase
AU - Reiter, Samantha
AU - Narjari, Riya
AU - Balakrishnan, Baskar
AU - Suksanpaisan, Lukkana
AU - Sakuma, Toshie
AU - Recker, Jordan
AU - Zhang, Lianwen
AU - Waniger, Scott
AU - Russell, Luke
AU - Petro, Christopher D.
AU - Kyratsous, Christos A.
AU - Baum, Alina
AU - Janecek, Jody L.
AU - Lee, Rachael M.
AU - Ramachandran, Sabarinathan
AU - Graham, Melanie L.
AU - Russell, Stephen J.
N1 - Funding Information:
We gratefully acknowledge the excellent and expert contributions of Carlen Hill, Jody Janecek, Ruby Klish, Rachael Lee, Christian Moses, Brenna Mulhollam, Lucas Mutch, Melanie Niewinski, Sierra Palmer, Scott Oppler, Jordan Truell for husbandry and clinical care of our animals, Mikayla Chavis, Sarah Gresch, Laura Hocum Stone for in vitro studies, Meghan Moore and Timothy O'Brien for pathology, and Mellani Lubaug, Margret Tavai-Tuisalo'o, Jade Wilder for administrative support at the University of Minnesota's Preclinical Research Center. We gratefully acknowledge the excellent and expert support of Parthasarathy Rangarajan, Naoya Sato, Anna Tran, Ravi Maisuria, Amar Singh, and Janice Anoka for sample processing and specimen archiving.
Publisher Copyright:
© 2021
PY - 2022/4/1
Y1 - 2022/4/1
N2 - An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.
AB - An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.
KW - Neutralizing antibodies
KW - Oral vaccine
KW - Rhabdovirus
KW - SARS-CoV-2
KW - T cells
KW - VSV
UR - http://www.scopus.com/inward/record.url?scp=85126104088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126104088&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.12.063
DO - 10.1016/j.vaccine.2021.12.063
M3 - Article
C2 - 35282925
AN - SCOPUS:85126104088
SN - 0264-410X
VL - 40
SP - 2342
EP - 2351
JO - Vaccine
JF - Vaccine
IS - 15
ER -